JUPITER, FL, December 8, 2011 – BioRestorative Therapies, Inc. (OTCQB: BRTX) (“BRT”) today announced that it has entered into a Material Manufacturing Agreement with the University of Utah. Pursuant to the agreement, the University of Utah has been retained to manufacture certain materials derived from stem cells.
The agreement marks the next step in the development of a strategic collaboration between BRT and the University of Utah, an institution recognized as a leader in translational stem cell-based therapies.
Dr. Amit Patel, Director of Clinical Regenerative Medicine and Tissue Engineering at the University of Utah, said, “We are pleased that we are expanding our relationship with BRT and are excited to be working with them on their scientific and clinical programs. The University’s stem cell laboratories have the unique skills and capacities to assist BRT in producing their stem cell derived materials.”
Mark Weinreb, Chairman and CEO of BRT, said, “BRT is fortunate to be partnering with the University of Utah and Dr. Patel’s team of stem cell experts. This represents the commencement of laboratory operations and we look forward to additional research and clinical collaborations.”